research use only
Cat.No.S9700
| Related Targets | Dehydrogenase HSP Transferase P450 (e.g. CYP17) PDE phosphatase PPAR Vitamin Carbohydrate Metabolism Mitochondrial Metabolism |
|---|---|
| Other AhR Inhibitors | BAY 2416964 Stemregenin 1 (SR1) CH-223191 BAY-218 FICZ Diosmin Norisoboldine PDM2 GNF351 CAY10465 |
|
In vitro |
DMSO
: 51 mg/mL
(200.53 mM)
Ethanol : 51 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 254.32 | Formula | C17H18O2 |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 79338-84-4 | -- | Storage of Stock Solutions |
|
|
| Synonyms | GSK2894512, Benvitimod, WBI 1001, DHPS, DMVT 505 | Smiles | CC(C)C1=C(O)C=C(\C=C\C2=CC=CC=C2)C=C1O | ||
| Targets/IC50/Ki |
AhR
(in immortalized keratinocytes) 0.16 nM(EC50)
apoptosis
(in CD4+ T cells) 5.2 μM
|
|---|---|
| In vitro |
Tapinarof binds and activates AhR in multiple cell types, including cells of the target tissue –human skin. In addition, this compound moderates proinflammatory cytokine expression in stimulated peripheral blood CD4+ T cells and ex vivo human skin, and impacts barrier gene expression in primary human keratinocytes; both of these processes are likely to be downstream of AhR activation based on current evidence. |
| In vivo |
The anti-inflammatory properties of tapinarof derive from AhR agonism is conclusively demonstrated using the mouse model of imiquimod-induced psoriasiform skin lesions. Topical treatment of AhR-sufficient mice with this compound leads to compound-driven reductions in erythema, epidermal thickening and tissue cytokine levels. In contrast, this chemical has no impact on imiquimod-induced skin inflammation in AhR-deficient mice. |
References |
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT05979896 | Recruiting | Malaria |
Malaria Consortium |
July 28 2023 | Phase 4 |
| NCT05478954 | Active not recruiting | Malaria |
Malaria Consortium |
July 15 2022 | Phase 4 |
| NCT05471544 | Active not recruiting | Malaria |
Malaria Consortium |
July 18 2022 | Phase 3 |
| NCT05326659 | Unknown status | Psoriasis |
Peking University People''s Hospital|Zhonghao Pharmaceutical |
April 2022 | Not Applicable |
| NCT05326672 | Unknown status | Atopic Dermatitis |
Peking University People''s Hospital|Zhonghao Pharmaceutical |
April 2022 | Phase 3 |
| NCT05172726 | Recruiting | Plaque Psoriasis |
Dermavant Sciences Inc. |
December 2 2021 | Phase 3 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.